New York Times: Lilly’s stock has surged in large part because of the company’s success in seizing the biggest potential market in the history of the drug industry: the class of weight loss medicines known as GLP-1s.
The company’s injection, sold as Zepbound and Mounjaro, is on track to be the top-selling drug in the world this year…